Describe risk reduction surgery. - from standard literature, if possible in an easy memorable format/Table
Your credits are exhausted. You can purchase a top-up or subscribe to a plan to continue using Orris. If you're already subscribed, your daily credits will reset tomorrow.
Describe risk reduction surgery. - make me an answer with current updates, standard book references, and suitable for md exam with exam prompts
Reading File
Searching PubMed
risk reduction surgery prophylactic mastectomy oophorectomy BRCA
Searching the Web
risk reduction surgery prophylactic surgery BRCA 2024 2025 guidelines update
Finding Sources
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC12961322
Reading File
Reading File
Reading File
Reading File
I now have excellent textbook and current guideline data. Let me compile a comprehensive, exam-focused answer.
Risk-Reduction (Prophylactic) Surgery
Definition
Surgical removal of an organ or tissue in a high-risk but currently cancer-free individual to substantially reduce the lifetime probability of developing cancer.
Quick-Reference Table: The 4 Core Procedures
| Procedure | Target Cancer | Key Indication | Risk Reduction |
|---|---|---|---|
| Bilateral Risk-Reducing Mastectomy (BRRM) | Breast | BRCA1/2, PALB2, TP53, CDH1, PTEN, STK11 | >90% breast cancer (Current Surgical Therapy 14e) |
| Risk-Reducing Salpingo-Oophorectomy (RRSO) | Ovarian/Fallopian tube | BRCA1/2 carriers | 96% gynecologic cancer; 50-80% breast cancer (pre-menopausal) (Berek & Novak's Gynecology) |
| Prophylactic Colectomy / IRA | Colorectal | FAP (familial adenomatous polyposis) | Near 100% colorectal |
| Total Gastrectomy | Gastric | CDH1 (E-cadherin) mutations (Hereditary Diffuse Gastric Cancer) | Very high; ~80% lifetime risk without surgery |
1. Bilateral Risk-Reducing Mastectomy (BRRM)
Indications
- BRCA1/2 pathogenic variants (lifetime breast risk ~72-85%)
- PALB2, TP53 (Li-Fraumeni), PTEN (Cowden), CDH1, STK11 (Peutz-Jeghers)
- Very strong family history even without confirmed mutation
- Lobular carcinoma in situ (LCIS) - selected cases
Risk Reduction
-
90% reduction in breast cancer risk in BRCA carriers
- Combined with RRSO: risk reduction up to ~95% (Myriad/NCCN data)
Types of Mastectomy Used (Current Surgical Therapy 14e)
| Type | What is Removed | When Used |
|---|---|---|
| Simple/Total Mastectomy | All breast tissue + NAC, no axillary nodes | No nodal involvement |
| Skin-Sparing Mastectomy | Breast tissue + NAC, skin envelope preserved | With reconstruction |
| Nipple-Sparing Mastectomy (NSM) | All breast tissue; NAC preserved | Most common for risk-reduction |
| Modified Radical | Breast + levels I-II axillary nodes | Proven nodal disease |
Exam Prompt: "NSM was historically reserved for prophylactic/risk-reduction mastectomy because of concern for occult tumor in the NAC." - Current Surgical Therapy 14e
Pre-op Checklist (NCCN)
- Genetic counseling confirmed
- Bilateral mammogram/MRI within 6 months
- Multidisciplinary team (genetics + surgery + reconstruction + oncology)
- Axillary node assessment NOT routinely required unless cancer found on pathology
2. Risk-Reducing Bilateral Salpingo-Oophorectomy (RRSO)
Who? (Gene-Stratified Timing)
| Gene | Ovarian Cancer Lifetime Risk | Recommended Timing of RRSO |
|---|---|---|
| BRCA1 | ~54% | Age 35-40, after childbearing |
| BRCA2 | ~23% | Age 40-45, after childbearing |
| Lynch syndrome | 6-12% | ~40 years or after childbearing |
| General high-risk family history | Variable | Individualized |
(Berek & Novak's Gynecology)
Benefits
- 96% reduction in BRCA-related gynecologic cancer (Berek & Novak's)
- Residual risk: peritoneal carcinoma remains (~0.8-1%) - because peritoneal epithelium shares embryological origin with ovarian surface epithelium
- 50-80% reduction in breast cancer risk, especially in BRCA2 carriers aged <50
Exam Prompt: "RRSO reduces breast cancer risk significantly in BRCA2 carriers aged <50 (HR 0.18, p=0.007) but NOT significantly in BRCA1 carriers aged <50 - likely because BRCA1 tumors are predominantly ER-negative and thus less hormone-sensitive."
Occult Malignancy at RRSO
- ~3-9.5% of high-risk women undergoing RRSO are found to have occult malignancy - emphasizes the need for thorough pathology (serial sectioning of fallopian tubes - the "SEE-FIM" protocol)
Add Hysterectomy?
- Not routinely recommended
- Consider in: BRCA1 carriers on tamoxifen (endometrial cancer risk), serous-type endometrial risk in BRCA1
- Decision must be individualized (Berek & Novak's)
Alternative: Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO)
- Proposed for women who want to delay menopause but still reduce risk
- Salpingectomy first (removes fallopian tube - the likely site of origin of HGSOC), oophorectomy later
- Under study; not yet standard (Creasy & Resnik's MFM)
3. Prophylactic Colectomy
Indication: Familial Adenomatous Polyposis (FAP)
- APC gene mutation; near 100% colorectal cancer risk if untreated
- Subtotal colectomy with ileorectal anastomosis (IRA) OR proctocolectomy + IPAA
- Timing: Late teens to early 20s (before polyposis progresses)
Lynch Syndrome (HNPCC): MSH2, MLH1, MSH6, PMS2, EPCAM
- Colorectal cancer risk ~40-80%; endometrial cancer risk ~40-60%
- Prophylactic hysterectomy + BSO considered in Lynch women after childbearing
- Subtotal colectomy for Lynch-associated colon cancer preferred over segmental
4. Total Prophylactic Gastrectomy
Indication: Hereditary Diffuse Gastric Cancer (HDGC)
- CDH1 (E-cadherin) mutation - ~80% lifetime gastric cancer risk
- Total gastrectomy recommended typically age 20-30 (or when pathogenic variant confirmed)
- No reliable surveillance alternative (signet ring cells invade submucosa and are invisible endoscopically until advanced)
5. Gene-Surgery Map (Exam Summary Table)
| Gene | Cancer Risk | Risk-Reduction Surgery |
|---|---|---|
| BRCA1 | Breast (72%), Ovary (54%) | BRRM + RRSO |
| BRCA2 | Breast (69%), Ovary (23%), Pancreas, Prostate | BRRM + RRSO |
| PALB2 | Breast (~53%) | BRRM (discuss) |
| TP53 | Breast, sarcoma, brain, adrenal | BRRM (radiation avoided; Li-Fraumeni) |
| PTEN | Breast (~85%), thyroid, endometrial | BRRM + hysterectomy (discuss) |
| CDH1 | Diffuse gastric (~80%), lobular breast | Total gastrectomy + BRRM |
| STK11 | GI, breast, pancreas | BRRM (discuss) |
| APC | Colorectal (~100%) | Colectomy |
| MLH1/MSH2 (Lynch) | Colorectal, endometrial | Colectomy, hysterectomy + BSO |
Pre-Operative Considerations (All Cases)
- Confirmed pathogenic variant by accredited genetic testing lab
- Genetic counseling - understanding of risks, alternatives, irreversibility
- Age and reproductive wishes (especially for RRSO)
- Alternatives discussed: chemoprevention (tamoxifen, raloxifene, aromatase inhibitors), enhanced surveillance (MRI, colonoscopy, endoscopy)
- Psychosocial support - body image, sexuality, premature menopause
- Multidisciplinary team decision
Chemoprevention vs. Surgery (Exam Comparison)
| Feature | Chemoprevention | Risk-Reduction Surgery |
|---|---|---|
| Tamoxifen | ~50% breast cancer reduction (NSABP-P1 trial); mainly ER+ tumors (BRCA2 benefit > BRCA1) | Not applicable |
| Raloxifene / AIs | Similar to tamoxifen; mainly postmenopausal | Not applicable |
| OCP | 60% ovarian cancer reduction (5+ years use; RR 0.4) | More effective but permanent |
| Surgery | Irreversible, side effects | 90-96% risk reduction |
Current Updates (2024-2026)
| Update | Details |
|---|---|
| Survival benefit confirmed (SABCS 2024) | Risk-reducing surgeries (bilateral mastectomy and/or RRSO) improve overall survival in early-onset BRCA carriers (aged ≤40 at diagnosis) - ASCO Post, Jan 2025 |
| NCCN v3.2025 | Advises discussion of BRRM for high-risk carriers; shared decision-making; considers fertility, psychosocial factors, morbidity |
| ESMO 2023 | Recommends offering BRRM after thorough counseling, based on age and family history |
| SSO 2025 | Aligns with NCCN; emphasizes shared decision-making especially for younger or surveillance-averse carriers |
| Non-BRCA variants (2025) | BRCA1/2 + PALB2: RRM preferred. TP53, CDH1, PTEN, STK11: individualized discussion. Moderate-penetrance variants (CHEK2, ATM, NF1): generally surveillance, not RRM (PMC12961322) |
| PSDO under study | Prophylactic salpingectomy + delayed oophorectomy - preserves ovarian function; fallopian tube origin of HGSOC supports this approach |
High-Yield Exam Mnemonics
"BRCA HITS" - what RRSO reduces:
- Breast cancer (50-80%, especially BRCA2 <50 yrs)
- Reproductive (ovarian) cancer (96%)
- Carcinoma peritonei (residual 0.8-1%)
- Auxiliary benefit: overall survival
"NSM = No Symptoms, Mostly" - nipple-sparing mastectomy historically for prophylaxis, now increasingly used therapeutically.
Classic Exam Vignette Pattern
"A 32-year-old woman with a confirmed BRCA1 pathogenic variant and strong family history of breast and ovarian cancer asks about risk-reduction options."
Answer framework:
- Confirm genetic counseling completed
- Offer BRRM (>90% breast cancer reduction) and RRSO (96% gynecologic cancer reduction, at age 35-40 for BRCA1)
- Discuss timing relative to childbearing
- Discuss chemoprevention as alternative/adjunct
- Discuss RRSO sequelae: surgical menopause, bone loss, cardiovascular effects, sexual dysfunction (systematically reviewed in PMID 37183167)
- Multidisciplinary approach
Sources:
- Current Surgical Therapy 14e - Mastectomy section, p.778
- Berek & Novak's Gynecology - Management of Women at High Risk for Ovarian Cancer, p.2324-2325
- Emery's Elements of Medical Genetics and Genomics - Treatment for high inherited cancer risk
- Creasy & Resnik's Maternal-Fetal Medicine - Prophylactic salpingectomy with delayed oophorectomy
- Risk-Reducing Mastectomy in BRCA1/2 - PMC 2025 review (NCCN v3.2025, ESMO 2023, SSO 2025 guidelines)
- ASCO Post Jan 2025 - Survival benefit data (SABCS 2024)
- Systematic Review, PMID 37183167 - post-surgical sexual function and menopausal effects
This is a shared conversation. Sign in to Orris to start your own chat.